A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90-MX-DTPA-CT8466) COMBINED WITH

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项I期试验，评价了在不可切除的局部晚期非小细胞CEA阳性肺癌患者中，添加作为单周期钇-90嵌合T84.66抗CEA抗体递送的放射免疫治疗联合标准外照射放射治疗和卡铂和紫杉醇化疗。该研究的目的是确定RIT的最大耐受剂量，可以与标准放化疗方案相结合。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I trial evaluating the addition of radioimmunotherapy deliverd as a single cycle of Yttrium-90 chimeric T84.66 anti CEA antibody in combination with standard external beam radiation therapy and Carboplatin and Paclitaxel chemotherapy for patients with unresectable locally advanced non-small cell CEA-positive lung cancer. The objective of the study is to determine the maximum tolerated dose of RIT that can be combined with the standard chemoradiotherapy regimen.